We have a diversified drug development pipeline across two therapeutic categories - oncology and CNS.
We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products and a portfolio of central nervous system, or CNS, product candidates. Our immuno-oncology portfolio is based off a proprietary technology platform consisting of single-chain bi-, tri- and tetra-specific scFv constructs, combined with proprietary antibody-drug linkers and drug payloads. Our CNS portfolio consists of innovative reformulations and/or repurposing of existing therapies that are covered by issued or filed composition of matter patents.
OXS-1550 is a bispecific scFv recombinant fusion protein-drug conjugate.
OXS-3550 is a trispecific ADCC NK Cell engager (TriKE).
OXS-1615 is a tetraspecific ADC in preclinical development that targets EpCAM+ present on the majority of solid tumors.
PainBrake is a new patented formulation of carbamazepine (Tegretolâ).
GTP-004 is a fixed dose combination tablet for the treatment of the muscle weakness.
GTP-011 is a 72-hour patch patented by GT Pharmaceuticals.